AbTis | 앱티스

AbTis is a biotechnology company with a proprietary linker platform, AbClick®, which enables the development of site-selective antibody conjugate therapies for the targeted delivery of diverse therapeutic payloads. Through AbClick®, AbTis has established a simple yet cost-efficient conjugation process that empowers the expansion of diverse forms of bioconjugate treatments, such as ADC, ARC, DAC, and others, all without modifying the antibody. AbClick® also allows for precise control over key parameters such as half-life, DAR, and linker-payload stability, which are all essential for designing optimal bioconjugate therapies. AbClick® is applicable to the native, commercial off-the-shelf, or novel antibodies under development as it requires no mutation or engineering to the antibody itself. Core competency is as follows. - Drug/payload conjugation to the unmodified mAb - Site-selective conjugation leading to precise control over DAR and half-life - Diversity of payload (both conventional and novel) including dual payload applications - Stability of linker-payload (minimize off-target, extracellular release of the payload)